Maasstad Ziekenhuis

Running trials

• Not yet recruiting

  Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Pirtobrutinib in Combination With Epcoritamab if the Disease Comes Back After Previous Treatment.

  NCT07860775· Phase 2· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Recruiting

  HO182 CLL: Treatment of patients with chronic lymphocytic leukemia (CLL) with 6 cycles of rituximab in combination with 6 or 26 cycles of venetoclax upon recurrence of the disease after previous treatment

  2025-524283-38-00· Phase 3· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Source

• Recruiting

  Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

  NCT07621809· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease

  2025-524001-33-00· Phase 2· Immunovant Sciences GmbH· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

• Not yet recruiting

  Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy

  NCT07486687· Phase 3· The Netherlands Cancer Institute· Source

• Not yet recruiting

  A study to assess the safety and efficacy of different doses of ELV001 to treat active rheumatoid arthritis in patients with an inadequate response to methotrexate and tumor necrosis factor inhibition (START SYNERGY)

  2025-524005-32-00· Phase 2· Elevara Medicines Limited· Source

• Enrolling by invitation

  Coronary Sinus Reducer in Coronary Microvascular Disease

  NCT06898541· UMC Utrecht· Source

• Recruiting

  NO Re-excision MelanomA - NORMA 2

  NCT07530887· Phase 3· Marieke Goodijk· Source

• Recruiting

  T3-4-Hypo trial

  2024-513883-24-00· Phase 3· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source

• Recruiting

  ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer

  NCT07188025· Phase 3· Erasmus Medical Center· Source

• Recruiting

  #AWARE.HIV Europe: Supporting Healthcare Professionals to Find Undiagnosed HIV in European Hospitals: An Effectiveness-implementation Trial.

  NCT06900829· Casper Rokx· Source

• Active, not recruiting

  A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)

  NCT07133633· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases

  NCT07160231· Phase 4· Sint Maartenskliniek· Source

• Recruiting

  Continuing ovulation induction with letrozole versus switching to gonadotropins in women with polycystic ovary syndrome (MOVIN-II study)

  2024-519354-36-00· Phase 4· Amsterdam UMC Stichting· Source

• Recruiting

  A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

  NCT07018323· Phase 2· Immunovant Sciences GmbH· Source

• Recruiting

  StAtins in Frail oldEr patients with ischemic Stroke or Transient ischemic attack – The Randomized Controlled Trial

  2024-517343-31-00· Phase 4· Amsterdam UMC Stichting· Source

• Active, not recruiting

  Multi-institutional Evaluation of the Cost-effectiveness of PSMA-PET/CT for the Detection of Pelvic Lymph Node Invasion in Newly Diagnosed Prostate Cancer Patients (PSMA-SELECT).

  2024-518171-59-00· Phase 4· Canisius Wilhelmina Ziekenhuis· Source

• Recruiting

  Tocilizumab Dose Optimization in Rheumatoid Arthritis

  2025-520513-30-00· Phase 4· Reade revalidatie & reumatologie centrum te Amsterdam· Source

• Recruiting

  Optimizing therapy with n=1-studies: negating the 'nocebo' effect in statin-intolerance

  2023-507489-20-00· Phase 4· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source

• Recruiting

  Stopping or continuing blood thinners after stroke at young age without a known cause: STOP trial

  2024-513092-40-00· Phase 4· Stichting Radboud universitair medisch centrum· Source

• Active, not recruiting

  Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine

  NCT06543914· AbbVie· Source

• Recruiting

  DAROTAXEL

  2024-516939-28-00· Phase 2· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source

• Active, not recruiting

  Dose tapering and Early Discontinuation to InCreAse cosT-effictIveness Of immunotherapy for Non-small cell lung carcinoma trial number 1 (NVALT-30 - Dedication-1)

  NCT04909684· Phase 3· Stichting Radboud universitair medisch centrum· Source

• Active, not recruiting

  Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS)

  NCT04225312· Phase 4· Amsterdam UMC Stichting· Source

• Recruiting

  DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer

  NCT06275958· Phase 3· Leiden University Medical Center· Source

• Recruiting

  Pro-RAPID

  NCT05552287· Phase 4· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source

• Recruiting

  FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)

  NCT06187441· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Recruiting

  A study with new methods to monitor newly diagnosed multiple myeloma in participants being treated with a new treatment combination - TAURUS

  NCT06189833· Phase 2· European Myeloma Network B.V.· Source

• Recruiting

  The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients

  NCT06082492· Radboud University Medical Center· Source

• Recruiting

  A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

  NCT05646381· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic Castration-sensitive Prostate Cancer

  NCT07260435· Phase 3· Nick Beije· Source

• Recruiting

  Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-volume castration-sensitive prostate cancer: a randomized Nationwide Study

  2023-506698-36-00· Phase 3· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source

• Recruiting

  A Phase III Prospective, Multicenter, Open-label Study to Assess Diagnostic Efficacy of a Novel 18F-labelled Tracer, SYN2, for Positron Emission Tomography in Subjects with Suspected Coronary Artery Disease

  2023-506971-89-00· Phase 3· Syn2bio S.A.· Source

• Recruiting

  PEnile ReHABilitation After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0 (PEHAB-II)

  NCT06875258· Phase 4· The Netherlands Cancer Institute· Source

• Active, not recruiting

  PEHAB II

  2023-507466-40-00· Phase 4· Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting· Source

• Active, not recruiting

  Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS

  2022-502664-21-00· Phase 4· Amsterdam UMC· Source

• Active, not recruiting

  Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients

  NCT05705973· Terumo Europe N.V.· Source

• Not yet recruiting

  COATS (genetic Clopidogrel response testing to finetune the antithrombotic regimen in (D)OAC Treated patients undergoing PCI) Study

  2024-512350-17-01· Phase 4· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source

• Recruiting

  High-Risk prostatE Cancer radiatiOn Versus surgERy

  NCT05931419· Comprehensive Cancer Centre The Netherlands· Source

• Recruiting

  National PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC)

  NCT05326620· PROspective Renal Cancer Cohort Foundation· Source

• Active, not recruiting

  The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD

  NCT05374291· Phase 3· University Medical Center Groningen· Source

• Active, not recruiting

  The Euro-CRAFT Registry

  NCT05805462· CoreAalst BV· Source

• Active, not recruiting

  Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

  NCT05243797· Phase 3· European Myeloma Network B.V.· Source

• Active, not recruiting

  SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)

  NCT05392608· Phase 2· Borstkanker Onderzoek Groep· Source

• Active, not recruiting

  Personalized dosing of ocrelizumab in MS

  2024-513193-22-00· Phase 4· Amsterdam UMC Stichting· Source

• Recruiting

  Vascular Events In Patients Undergoing Same-day Noncardiac Surgery (VALIANCE) Study

  NCT04973397· Centre hospitalier de l'Université de Montréal (CHUM)· Source

• Recruiting

  The PIONEER-IV Study is Comparing Clinical Outcomes Between Angiography-derived Physiology Guidance to Usual Care in an All-comers PCI Population With Unrestrictive Use of the HT Supreme Sirolimus-eluting Stent

  NCT04923191· National University of Ireland, Galway, Ireland· Source

• Active, not recruiting

  Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer

  NCT04927780· Phase 3· Erasmus Medical Center· Source

• Active, not recruiting

  Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

  NCT04608318· Phase 3· German CLL Study Group· Source

Showing 50 of 63.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Coronary artery disease7 recruiting
• Prostate cancer5 recruiting
• Chronic lymphocytic leukaemia3 recruiting
• Colorectal cancer3 recruiting
• Rheumatoid arthritis3 recruiting
• Ankylosing spondylitis2 recruiting
• Stroke2 recruiting
• ANCA-associated vasculitis1 recruiting
• Aortic stenosis1 recruiting
• Childhood cancers1 recruiting
• Crohn's disease1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Graves' disease and hyperthyroidism1 recruiting
• Heart failure1 recruiting
• HIV1 recruiting
• Hypothyroidism1 recruiting
• Kidney cancer1 recruiting
• Lung cancer1 recruiting
• Melanoma1 recruiting
• Multiple myeloma1 recruiting
• Obesity1 recruiting
• Polycystic ovary syndrome1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Sjögren's disease1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  A Study With CIT-013 in RA Patients

  NCT06567470· Phase 2· Citryll BV· Source

• Completed

  THE (COST)EFFECTIVENESS OF NEOADJUVANT FOLFIRINOX VERSUS NEOADJUVANT GEMCITABINE BASED CHEMORADIOTHERAPY AND ADJUVANT GEMCITABINE FOR (BORDERLINE) RESECTABLE PANCREATIC CANCER (PREOPANC-2 STUDY)

  2024-516260-29-00· Phase 3· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source

• Completed

  Comparing the effectiveness of our tailor-made management approach with routine care from a clinical, patient's as well as an economic point of view. Tailoring of treatment is done by taking the presence of autoantibodies and the quick response to glucocorticoids and JAK inhibitors into account.

  2024-511530-12-01· Phase 4· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source

• Active, not recruiting

  Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

  NCT06293365· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Effect of Music Prehabilitation on Preoperative Anxiety Before Surgery

  NCT05982184· Erasmus Medical Center· Source

• Completed

  A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF

  NCT05911360· Phase 3· ViiV Healthcare· Source

• Completed

  A Clinical Trial to Assess the Elixir Medical LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter

  NCT05828173· Elixir Medical Corporation· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Active, not recruiting

  Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

  NCT05147220· Phase 3· Novartis Pharmaceuticals· Source

• Terminated

  ACT Guided Heparinization During Open Abdominal Aortic Aneurysm Repair.

  NCT04061798· Phase 4· Dijklander Ziekenhuis· Source

• Completed

  Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)

  NCT04026113· Phase 3· AbbVie· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Amgen· Source

• Completed

  Safety and Efficiency of the YEARS Algorithm Versus Computed Tomography Pulmonary Angiography Alone for Suspected Pulmonary Embolism in Patients With Malignancy

  NCT04657120· Leiden University Medical Center· Source

• Completed

  Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223· Phase 3· CSL Behring· Source

• Completed

  PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease

  NCT03168776· Sino Medical Sciences Technology Inc.· Source

• Completed

  A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in physically fit patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations, HOVON 141 CLL / VIsion Trial of the HOVON and Nordic CLL study groups

  NCT03226301· Phase 2· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Source

• Completed

  A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug

  NCT03104374· Phase 3· AbbVie· Source

• Completed

  A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

  NCT03104400· Phase 3· AbbVie· Source

• Completed

  Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

  NCT02947347· Phase 3· Pharmacyclics LLC.· Source

• Completed

  autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial

  2024-511235-10-00· Phase 3· Klinikum der Universitaet Muenchen AöR· Source

• Completed

  Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases

  NCT02162563· Phase 3· Dutch Colorectal Cancer Group· Source